Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.

Phase 4

Recruiting

• Conditions: Peripheral Arterial Disease
• Interventions: Genetic: Direct CYP2C19 genotyping; Genetic: CYP2C19 genotyping at the end of the study; Drug: Poor metabolisers; Drug: Intermediate metabolisers; Drug: Normal metabolisers and unknown metaboliser state

• Registration Number: NCT04619927
• Lead Sponsor: Radboud University Medical Center

Brief Summary

Rationale: Peripheral arterial disease (PAD) is a common presentation of atherosclerosis. For the prevention of adverse events related to arterial thrombosis in PAD patients, clopidogrel is recommended. Clopidogrel in itself is inactive and needs to be metabolized by cytochrome P450 2C19 (CYP2C19) into the active metabolite. About 30% of PAD patients receiving clopidogrel is carrying one or two CYP2C19 loss-of-function allele(s) and do not or to a limited extent convert the prodrug into its active metabolites, and are therefore at increased risk of adverse clinical events related to arterial thrombosis. We hypothesize that genotype-guided prescription of antithrombotic treatment reduces adverse clinical events related to arterial thrombosis.

Objective: The primary aim of the GENPAD study is to evaluate the ability of genotype-guided antithrombotic treatment to reduce adverse clinical events related to arterial thrombosis in PAD patients. Secondary objectives are to evaluate the ability of genotype-guided antithrombotic treatment to reduce the separate elements of the primary composite outcome and to assess the risk of clinically relevant bleedings in patients allocated to the genotype-guided antiplatelet treatment versus standard clopidogrel prescription.

Study design: A randomized, controlled, open label, multicenter trial. Study population: Patients (n=2276) with PAD consulting a vascular surgeon for diagnosis and/or treatment, receiving clopidogrel according to the guidelines.

Intervention: Testing for carriage of the CYP2C19\*2 and \*3 loss-of-function alleles, followed by a genotype guided antithrombotic treatment with either clopidogrel 75mg once daily (normal metabolizers), clopidogrel 75mg twice daily (intermediate metabolizers), or low-dose rivaroxaban plus acetylsalicylic acid (poor metabolizers).

Comparator: All patients receive clopidogrel 75mg once daily without pharmacogenetic guidance.

Main study parameters/endpoints: The primary combined outcome is the occurrence of adverse clinical events related to arterial thrombosis at 24 months. The occurrence of major adverse cardiovascular events, major adverse limb events, death and clinically relevant bleedings are the secondary endpoints.

Detailed Description

Rationale: Peripheral arterial disease (PAD) is a common presentation of atherosclerosis, resulting in intermittent claudication, pain at rest or gangrene. For the prevention of adverse events related to arterial thrombosis in PAD patients, clopidogrel is recommended. Clopidogrel in itself is inactive and needs to be metabolized by cytochrome P450 2C19 (CYP2C19) into the active metabolite. About 30% of PAD patients receiving clopidogrel is carrying one or two CYP2C19 loss-of-function allele(s) and do not or to a limited extent convert the prodrug into its active metabolites, and are therefore at increased risk of adverse clinical events related to arterial thrombosis and subsequent cardiovascular death. We hypothesize that genotype-guided prescription of antithrombotic treatment reduces adverse clinical events related to arterial thrombosis.

Objective: The primary aim of the GENPAD study is to evaluate the ability of genotype-guided antithrombotic treatment to reduce adverse clinical events related to arterial thrombosis in PAD patients. Adverse clinical events of interest are major adverse cardiovascular events (myocardial infarction, stroke, transient ischemic arrack), major adverse limb events (acute/chronic limb ischemia of peripheral vascular intervention including amputation) and death. Secondary objectives are to evaluate the ability of genotype-guided antithrombotic treatment to reduce the separate elements of the primary composite outcome and to assess the risk of clinically relevant bleedings in patients allocated to the genotype-guided antiplatelet treatment versus standard clopidogrel prescription. Other objectives are to evaluate cost-effectiveness, to explore health state scores and health-related quality of life between study groups and metabolizer states and to set-up a biobank.

Study design: A randomized, controlled, open label, multicenter trial. Study population: Patients (n=2276) with PAD consulting a vascular surgeon for diagnosis and/or treatment, receiving clopidogrel according to the guidelines.

Intervention: Testing for carriage of the CYP2C19\*2 and \*3 loss-of-function alleles, followed by a genotype guided antithrombotic treatment with either clopidogrel 75mg once daily (normal metabolizers), clopidogrel 75mg twice daily (intermediate metabolizers), or low-dose rivaroxaban plus acetylsalicylic acid (poor metabolizers).

Comparator: All patients receive clopidogrel 75mg once daily without pharmacogenetic guidance.

Main study parameters/endpoints: The primary combined outcome is the occurrence of adverse clinical events related to arterial thrombosis at 24 months. The occurrence of major adverse cardiovascular events, major adverse limb events, death and clinically relevant bleedings are the secondary endpoints. Health state, quality of life and medical consumption will be measured with validated questionnaire. Questionnaires will be used to assess which antithrombotic treatment the participant is receiving during follow-up, medication adherence and the occurrence of extramural adverse events at 6, 12, 24 and 36 months.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants will visit the hospital once for informed consent procedure, blood sample withdrawal and/or buccal sample collection This visit will be combined with a routine visit to the vascular surgeon or vascular laboratory. Patients might experience some discomfort while taking blood samples and buccal sample collection for a short amount of time. The follow-up of participants will range from 6 months (minimum) to 36 months (maximum). Participants are sent questionnaires at baseline and at 6, 12, 24 and 36 months, dependent on the duration of their follow-up. Completing the questionnaires will take approximately 30 minutes. Risks regarding the study are negligible and consist of the possible adverse events related to doubling the daily dose of clopidogrel or related to rivaroxaban and acetylsalicylic acid.

Study Timeline

• Study First Submitted: 2020-11-02
• Study First Submitted QC: 2020-11-02
• Study First Posted: 2020-11-06
• Study Start: 2021-03-01
• Status Verified: 2022-01
• Last Update Submitted: 2022-04-19
• Last Update Posted: 2022-04-20
• Primary Completion: 2024-06-30
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 2276

Inclusion Criteria

• Age > 16 years
• Obtained written informed consent
• Indication for monotherapy clopidogrel 75mg once daily
• Ankle-brachial index < 0.9 and/or toe brachial index < 0.5
• Current or previous symptoms due to insufficient vascularization of one or two lower extremities, including intermittent claudication, pain at rest and/or gangrene (Rutherford category 1-6)
• Consulting a vascular surgeon for diagnosis, treatment and/or follow-up of PAD

Read More

Exclusion Criteria

• known CYP2C19 genotype or metabolizer state
• treated with coumarins, Non-vitamin K Oral Anti-Coagulants, unfractionated heparin, low molecular weight heparins or double antiplatelet therapy with acetylsalicylic acid and a P2Y12 inhibitor for other indications
• contraindication for clopidogrel, acetylsalicylic acid and/or rivaroxaban
• pregnant or breastfeeding women
• unable to give informed consent (including not being able to understand the Dutch language)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention group	Direct CYP2C19 genotyping	The intervention includes testing of patients for carriage of the CYP2C19\*2 and \*3 allele (loss-of-function (LOF) alleles), followed by a genotype guided antithrombotic treatment with either clopidogrel 75mg (without LOF allele, normal metabolizers), clopidogrel 150mg (one LOF allele, intermediate metabolizers), or rivaroxaban 2.5mg twice daily plus acetylsalicylic acid 100mg (two LOF alleles, poor metabolizers).
Intervention group	Normal metabolisers and unknown metaboliser state	The intervention includes testing of patients for carriage of the CYP2C19\*2 and \*3 allele (loss-of-function (LOF) alleles), followed by a genotype guided antithrombotic treatment with either clopidogrel 75mg (without LOF allele, normal metabolizers), clopidogrel 150mg (one LOF allele, intermediate metabolizers), or rivaroxaban 2.5mg twice daily plus acetylsalicylic acid 100mg (two LOF alleles, poor metabolizers).
Comparison group	CYP2C19 genotyping at the end of the study	The comparison group will not be prescribed clopidogrel 75mg without preceding testing for carriage of the CYP2C19\*2 and \*3 loss-of-function alleles. CYP2C19 genotyping will be performed at the end of the study.
Intervention group	Poor metabolisers	The intervention includes testing of patients for carriage of the CYP2C19\*2 and \*3 allele (loss-of-function (LOF) alleles), followed by a genotype guided antithrombotic treatment with either clopidogrel 75mg (without LOF allele, normal metabolizers), clopidogrel 150mg (one LOF allele, intermediate metabolizers), or rivaroxaban 2.5mg twice daily plus acetylsalicylic acid 100mg (two LOF alleles, poor metabolizers).
Intervention group	Intermediate metabolisers	The intervention includes testing of patients for carriage of the CYP2C19\*2 and \*3 allele (loss-of-function (LOF) alleles), followed by a genotype guided antithrombotic treatment with either clopidogrel 75mg (without LOF allele, normal metabolizers), clopidogrel 150mg (one LOF allele, intermediate metabolizers), or rivaroxaban 2.5mg twice daily plus acetylsalicylic acid 100mg (two LOF alleles, poor metabolizers).
Comparison group	Normal metabolisers and unknown metaboliser state	The comparison group will not be prescribed clopidogrel 75mg without preceding testing for carriage of the CYP2C19\*2 and \*3 loss-of-function alleles. CYP2C19 genotyping will be performed at the end of the study.

Primary Outcome Measures

Name	Time	Method
The number of participants that experienced major adverse events	24 months	The number of participants that experienced a major adverse cardiovascular events, major adverse limb events or death from any cause.

Secondary Outcome Measures

Name	Time	Method
The number of participants that experienced major adverse limb events	24 months	The number of participants that experienced acute limb ischemia, chronic limb ischemia or peripheral vascular intervention
The number of participants that experienced major adverse cardiovascular events	24 months	The number of participants that experienced a myocardial infarction, stroke, transient ischemic attack or cardiovascular death.
The number of participants that experienced major bleeding	24 months	The number of participants that experienced major bleeding, including: 1) fatal bleeding, 2) symptomatic bleeding into a critical organ, 3) bleeding causing a fall in hemoglobin level of 20 g L-1 (1.24 mmol L-1) or more or leading to transfusion of two or more units of whole blood or red cells, and 4) bleeding into a surgical site requiring a second intervention.
The number of participants that experienced clinically relevant bleeding	24 months	The number of participants that experienced clinically relevant bleeding, including bleeding that led to: 1) hospitalization (including presentation to an acute care facility without an overnight stay), 2) a physician guided medical or surgical treatment for bleeding, or 3) a change in antithrombotic treatment.

Trial Locations

Locations (11)

Medisch Spectrum Twente; 🇳🇱 Enschede, Netherlands

Canisius Wilhelmina Hospital; 🇳🇱 Nijmegen, Netherlands

UMC Groningen; 🇳🇱 Groningen, Netherlands

Ziekenhuis Gelderse Vallei; 🇳🇱 Ede, Netherlands

Rijnstate; 🇳🇱 Arnhem, Netherlands

Gelre Ziekenhuizen; 🇳🇱 Apeldoorn, Netherlands

Máxima Medisch Centrum; 🇳🇱 Eindhoven, Netherlands

Ommelander Ziekenhuis; 🇳🇱 Groningen, Netherlands

Maastricht University Medical Center; 🇳🇱 Maastricht, Netherlands

Radboudumc; 🇳🇱 Nijmegen, Netherlands

Bernhoven; 🇳🇱 Uden, Netherlands